Clinical study of Acetylkitasamycin Dry Suspension in treatment of Mycoplasma pneumoniae pneumonia in children
Objective To observe the clinical efficacy and safety of Acetylkitasamycin Dry Suspension on Mycoplasma pneumoniae pneumonia(MPP)in children.Methods From April 2022 to May 2023,the children with MPP diagnosed in Zhaoqing Maternal and Child Health Hospital were collected as the research objects.The subjects were randomly divided into a treatment group(oral administrate Acetylkitasamycin Dry Suspension)and a control group(oral administrate Azithromycin Dry Suspension).The two groups were given routine treatment,including basic symptomatic treatment such as antipyretic,relieving cough,resolving phlegm and relieving asthma,The treatment last for 1-2 weeks.Compare with the clinical efficacy of the two groups after treatment,disappearance and adverse drug reactions during treatment were compared before and after treatment.Results There were 60 cases in treatment group and 60 cases in control group.During the treatment period,six children were dropped out or lost to follow-up.Two group drugs can effectively improve the symptoms of fever,cough,sputum and pans.At interview 1[(5±2)days after the first dose],the improvement rate of crackles baseline and efficiency in the Acetylkitasamycin Dry Suspension group were better than that in Azithromycin group,which may indicate that acetylkitasamycin has a faster effect on MPP.At the interview 2[(10±2)days after the first administration],Acetylkitasamycin Dry Suspension had a better remission rate of cough symptoms than azithromycin,but could not be ruled out the influence of ages.During the treatment period,the incidences of adverse drug reactions in treatment group and control group during treatment were no significant difference(P＞0.05).Through the survey of compliance,two groups have good medical compliance.Conclusion Acetylguitamycin Dry Suspension can effectively treat MPP Children with good compliance and tolerance.Acetylkitasamycin Dry Suspension has good clinical efficacy in treatment of children with MPP advantages in onset time and remission rate of cough symptoms.
NETL
NSTL
万方数据
